PMID- 34933240
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20221221
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Print)
IS  - 1043-4666 (Linking)
VI  - 150
DP  - 2022 Feb
TI  - Effect of SARS-CoV-2 seropositivity on antigen - specific cytokine and chemokine 
      responses in latent tuberculosis.
PG  - 155785
LID - S1043-4666(21)00374-4 [pii]
LID - 10.1016/j.cyto.2021.155785 [doi]
AB  - SARS-CoV-2 and latent Mycobacterium tuberculosis infection are both highly 
      co-prevalent in many parts of the globe. Whether exposure to SARS-CoV-2 
      influences the antigen specific immune responses in latent tuberculosis has not 
      been investigated. We examined the baseline, mycobacterial antigen and mitogen 
      induced cytokine and chemokine responses in latent tuberculosis (LTBI) 
      individuals with or without SARS-CoV-2 seropositivity, LTBI negative individuals 
      with SARS-CoV-2 seropositivity and healthy control (both LTBI and SARS-CoV-2 
      negative) individuals. Our results demonstrated that LTBI individuals with 
      SARS-CoV-2 seropositivity (LTBI+/IgG +) were associated with increased levels of 
      unstimulated and TB-antigen stimulated IFNgamma, IL-2, TNFalpha, IL-17, IL-1beta, IL-6, 
      IL-12, IL-4, CXCL1, CXCL9 and CXCL10 when compared to those without 
      seropositivity (LTBI+/IgG-). In contrast, LTBI+/IgG+ individuals were associated 
      with decreased levels of IL-5 and IL-10. No significant difference in the levels 
      of cytokines/chemokines was observed upon mitogen stimulation between the groups. 
      SARS-CoV-2 seropositivity was associated with enhanced unstimulated and 
      TB-antigen stimulated but not mitogen stimulated production of cytokines and 
      chemokines in LTBI+ compared to LTBI negative individuals. Finally, most of these 
      significant differences were not observed when LTBI negative individuals with 
      SARS-CoV-2 seropositivity and controls were examined. Our data clearly 
      demonstrate that both baseline and TB - antigen induced cytokine responses are 
      augmented in the presence of SARS-CoV-2 seropositivity, suggesting an augmenting 
      effect of prior SARS-CoV-2 infection on the immune responses of LTBI individuals.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - Rajamanickam, Anuradha
AU  - Rajamanickam A
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India. Electronic address: anuradha@nirt.res.in.
FAU - Pavan Kumar, Nathella
AU  - Pavan Kumar N
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Chandrasekaran, Padmapriyadarsini
AU  - Chandrasekaran P
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Nancy, Arul
AU  - Nancy A
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
FAU - Bhavani, P K
AU  - Bhavani PK
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Selvaraj, Nandhini
AU  - Selvaraj N
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
FAU - Karunanithi, Kushiyasri
AU  - Karunanithi K
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Munisankar, Saravanan
AU  - Munisankar S
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
FAU - Srinivasan, R
AU  - Srinivasan R
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Mariam Renji, Rachel
AU  - Mariam Renji R
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
FAU - Priya Kumaravadivelu, Shanmuga
AU  - Priya Kumaravadivelu S
AD  - ICMR-National Institute for Research in Tuberculosis, Chennai, India.
FAU - Venkatramani, Vijayalakshmi
AU  - Venkatramani V
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
FAU - Babu, Subash
AU  - Babu S
AD  - ICMR-National Institute for Research in Tuberculosis-International Center for 
      Excellence in Research, Chennai, India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211214
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Phytohemagglutinins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood
MH  - Antigens, Bacterial/immunology
MH  - COVID-19/*complications/immunology
MH  - Chemokines/blood
MH  - Cytokines/*blood
MH  - Female
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunoglobulin G/blood
MH  - Inflammation
MH  - Latent Tuberculosis/blood/*complications/immunology
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Middle Aged
MH  - Phytohemagglutinins/pharmacology
MH  - SARS-CoV-2/*immunology
MH  - Seroconversion
PMC - PMC8668379
OTO - NOTNLM
OT  - Antigen specific responses
OT  - Chemokines
OT  - Cytokines
OT  - LTBI
OT  - SARS-CoV-2 seropositivity
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2021/12/22 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/12/14
CRDT- 2021/12/21 20:24
PHST- 2021/04/15 00:00 [received]
PHST- 2021/10/20 00:00 [revised]
PHST- 2021/12/07 00:00 [accepted]
PHST- 2021/12/22 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/12/21 20:24 [entrez]
PHST- 2021/12/14 00:00 [pmc-release]
AID - S1043-4666(21)00374-4 [pii]
AID - 155785 [pii]
AID - 10.1016/j.cyto.2021.155785 [doi]
PST - ppublish
SO  - Cytokine. 2022 Feb;150:155785. doi: 10.1016/j.cyto.2021.155785. Epub 2021 Dec 14.